LogicBio Therapeutics Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics or view top-rated stocks.

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for LogicBio Therapeutics.

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) announced its earnings results on Monday, May, 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.06. The firm had revenue of $0.46 million for the quarter.
View LogicBio Therapeutics' earnings history.

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LOGC shares have decreased by 37.4% and is now trading at $4.41.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1-year price targets for LogicBio Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect LogicBio Therapeutics' stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 293.0% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to LogicBio Therapeutics include Ikena Oncology (IKNA), Harpoon Therapeutics (HARP), Autolus Therapeutics (AUTL), Gritstone bio (GRTS), Achilles Therapeutics (ACHL), Lineage Cell Therapeutics (LCTX), Black Diamond Therapeutics (BDTX), Codiak BioSciences (CDAK), Solid Biosciences (SLDB), Outlook Therapeutics (OTLK), Athira Pharma (ATHA), SQZ Biotechnologies (SQZ), AVROBIO (AVRO), Jounce Therapeutics (JNCE) and Adverum Biotechnologies (ADVM).
View all of LOGC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

(LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

LogicBio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Samlyn Capital LLC (4.35%), BlackRock Inc. (3.06%), EcoR1 Capital LLC (2.14%), Pura Vida Investments LLC (0.79%), JPMorgan Chase & Co. (0.75%) and Geode Capital Management LLC (0.71%). Company insiders that own LogicBio Therapeutics stock include Bioscience Plc Arix, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends for LogicBio Therapeutics.

LOGC stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, JPMorgan Chase & Co., Samlyn Capital LLC, Morgan Stanley, Northern Trust Corp, and Verition Fund Management LLC. Company insiders that have sold LogicBio Therapeutics company stock in the last year include Bioscience Plc Arix, Frederic Chereau, and Kyle Chiang.
View insider buying and selling activity for LogicBio Therapeutics or view top insider-selling stocks.

LOGC stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, Trexquant Investment LP, Squarepoint Ops LLC, Texas Yale Capital Corp., and Barclays PLC.
View insider buying and selling activity for LogicBio Therapeutics or or view top insider-buying stocks.

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LOGC stock can currently be purchased for approximately $4.41.

LogicBio Therapeutics has a market capitalization of $141.83 million and generates $3.45 million in revenue each year. The company earns $-32,620,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

LogicBio Therapeutics employs 39 workers across the globe.

The official website for LogicBio Therapeutics is www.logicbio.com.

LogicBio Therapeutics is headquartered at 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421.

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]